BioHarvest Sciences, Inc. · NASDAQ:BHST
BioHarvest Sciences — Investor Presentation (May 2026)
29 slides from BioHarvest Sciences's investor presentation, May 2026
Slide 1: Corporate Presentation
The Botanical Synthesis Company CORPORATE PRESENTATION May 2026 Nasdaq: BHST NASDAQ: BHST 01
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS Cautionary Note Regarding Forward-Looking Statements This presentation contains "forward-looking statements." The statements contained in this presentation that are not purely historical are forward-looking statements. Forward-looking statements give the Company's current
Slide 3: Our Mission
OUR MISSION NATURAL BHST is addressing unmet health and wellness needs with patentable plant compounds produced consistently and economically with PHARMA/ NUTRACEUTICALS the highest levels of sustainability. BIOTECH PROPRIETARY SUSTAINABLE PLANT BASES CONSISTENT MOLECULES The North Star of BHST is t
Slide 4: BioHarvest Introduction
BIOHARVEST INTRODUCTION BIOHARVEST IS THE INVENTOR OF BOTANICAL SYNTHESIS – THE PROCESS OF ISOLATING AND MAXIMIZING THE POTENCY OF PHYTO-NUTRIENTS/MEDICINAL COMPOUNDS FROM PLANTS FOR COMMERCIAL APPLICATIONS BY GROWING ONLY PLANT CELLS WITHOUT GROWING THE PLANT COMPANY HIGHLIGHTS Q4 RESULTS Patented
Slide 5: Executive Leadership Team
EXECUTIVE LEADERSHIP TEAM DR. ZAKI RAKIB DR. YOCHI HAGAY BAR DICHTER DR. MALKIT AZACHI DR. ILANA BELZER Co-Founder, Executive Chief Technology Chief Financial Officer Vice President R&D Chief Operating Officer Chairman and Chief Officer 8+ years experience leading 20+ years experience Extensive expe
Slide 6: Fourth Quarter 2025 Highlights
FOURTH QUARTER 2025 HIGHLIGHTS LAYING THE FOUNDATIONS FOR LONG-TERM GROWTH & PROFITABILITY $45m 2024 $40m $25.2m 57% 55% $35m $34.5m REVENUES YE Gross Margins Q4 Gross Margins YE $30m +37% Q4 $9.1m $25.2m $25m 2025 Q4 +25% $7.3m $34.5m +37% 58% +100 bp 59% +400 bp $20m REVENUES YE Gross Margins Q4 G
Slide 7: Our Proprietary Technology Process
OUR PROPRIETARY TECHNOLOGY PROCESS A Global Leader in Plant Cell Biology with 15+ Years of Development and ~$100M Invested in the Platform WE ONLY REQUIRE THE PLANT ONCE TO MIRROR, MAGNIFY AND MULTIPLY PLANT CELLS WITH UNIQUE PHYTOMEDICINAL COMPOUNDS. CELL PERFORMED THE ISOLATION, MIRRORING CELL & O
Slide 8: Turning Plants into a Scientifically Reliable Source of Patentable Compounds
TURNING PLANTS INTO A SCIENTIFICALLY RELIABLE SOURCE OF PATENTABLE BIOLOGICAL COMPOUNDS Botanical Synthesis Offers Significant Advantages in Production of Simple and Complex Compounds Consistency Patentability Optimal Bioavailability Production inherently has a degree of control Botanical compositio
Slide 9: Two Growth Engines to Drive Growth
TWO GROWTH ENGINES TO DRIVE GROWTH Providing Validation For Botanical Synthesis And Strategic Optionality DIRECT TO CONSUMER – PACKAGED PRODUCTS CDMO Services Commercial Formulation Complete TBD APPLYING BOTANICAL SYNTHESIS AS A CDMO TO DEVELOP PLANT-BASED COMPOUNDS FOR: Vinia Olivia Pomia • MULTIPL
Slide 10: Introducing Vinia: Our Flagship Red Grape Cell-Derived Product
INTRODUCING VINIA®: OUR FLAGSHIP RED GRAPE CELL-DERIVED DIRECT-TO-CONSUMER NUTRACEUTICAL PRODUCT • VINIA® is BioHarvest’s first commercial product. Proof-of-concept and market acceptance with over $84M in lifetime sales since 2021. • Breakthrough Red Grape Cell Powder that is Clinically shown to sig
Slide 11: Products Anchored in Science & Backed by Clinical Trials
PRODUCTS ANCHORED IN SCIENCE & BACKED BY CLINICAL TRIALS VINIA® is patent-protected with 3 peer-reviewed studies and 8 scientific studies Clinical trial published in peer reviewed scientific journals bioharvest.com/clinical-studies *These statements have not been evaluated by the Food and Drug Admin
Slide 12: NASDAQ: BHST
NASDAQ: BHSTBHST NASDAQ: 12
Slide 13: Our Disruptive Category Playbook
OUR DISRUPTIVE CATEGORY PLAYBOOK ACCESSES MAJOR BILLION- DOLLAR CATEGORIES USA HEART HEALTH, ENERGY HEALTH & MENTAL ALERTNESS MARKET – $13 BN USA HYDRATION MARKET – $13 BN BILLION MAY- 21 JUNE - 25 DEC- 2025 USA FUNCTIONAL COFFEE AND TEA MARKET – $5 BN DEC- 23 In Development DEC- 24 JUNE- 25 - "Func
Slide 14: Bioreactors for Illustration Purposes Only
BIOREACTORS FOR ILLUSTRATION PURPOSES ONLY NASDAQ: BHSTBHST NASDAQ: 14
Slide 15: Our Vinia Brand Has Achieved Major Milestones
OUR VINIA BRAND HAS ACHIEVED A MAJOR MILESTONES #1 Resveratrol Polyphenol Brand in the U.S.* Achieved in less than five years since U.S. market entry in May 2021 > 85,000 active VINIA® users reached for the brand globally as of end March 2026 SOLD APPROX $84M OF VINIA PRODUCTS SINCE SCALING IN 2021
Slide 16: Our Breakthrough Positioning
OUR BREAKTHROUGH POSITIONING BETTER BLOOD FLOW. >$1 BILLION annually BETTER HYDRATION. >$200 MILLION annually 45 CAL PER STICK 25 CAL 10 CAL 68% 80% SALT SUGAR (1000mg) SUPER SWEET WELL BALANCED CLEAN TASTE SUPER SALTY NATURALY SOURCED ELECTROLYTES 11 GRAMS PICEID RESVERATROL & POLYPHENOLS 1000mg AD
Slide 17: Our Breakthrough Positioning
OUR BREAKTHROUGH POSITIONING >$1 BILLION annually BETTER BLOOD FLOW. BETTER HYDRATION. >$200 MILLION annually 45 CAL PER STICK 25 CAL 10 CAL 68% 80% SALT SUGAR (1000mg) SUPER SWEET WELL BALANCED CLEAN TASTE SUPER SALTY NATURALY SOURCED ELECTROLYTES 11 GRAMS PICEID RESVERATROL & POLYPHENOLS 1000mg AD
Slide 18: Blood Flow Hydration Early Success
BLOOD FLOW HYDRATION EARLY SUCCESS “ELECTROLYTES POWERING CELLS THROUGH BETTER BLOOD FLOW DELIVERY” #2 contributor to new customer TOP PERFORMANCE RATINGS FROM sales for VINIA, playing a key role CONSUMERS in driving consistent acquisition and growth Rating of 4.8/5 on VINIA.com after ~100 reviews R
Slide 19: BioHarvest Distribution Strategy for D2C Business
BIOHARVEST DISTRIBUTION STRATEGY FOR D2C BUSINESS: Significant untapped potential in new major channels and geographies ~95% of Business CURRENT SCALE HAS CREATED LEVERAGE WITH MAJOR UNTAPPED DISTRIBUTION EXPANSION OPPORTUNITIES 1. Proprietary BioHarvest Built Channel – VINIA Health Pro’s ~80% of Re
Slide 20: Repeating the Vinia Playbook
REPEATING THE VINIA PLAYBOOK: PIPELINE OF OLIVE AND POMEGRANATE CELLS Business Model Can be Easily Replicated Across New Plant Compounds • Olives: Providing at least 15X concentrated amounts of Verbascoside concentration vs. a regular olive: a compound with antioxidant, anti-inflammatory and antineo
Slide 21: Two Growth Engines to Drive Growth
TWO GROWTH ENGINES TO DRIVE GROWTH Providing Validation For Botanical Synthesis And Strategic Optionality DIRECT TO CONSUMER – PACKAGED PRODUCTS CDMO Services Commercial Expected 2026 Launch TBD APPLYING BOTANICAL SYNTHESIS AS A CDMO TO DEVELOP PLANT-BASED COMPOUNDS FOR: Vinia Olivia Pomia • MULTIPL
Slide 22: CDMO Engine for Growth Across Major Industries
CDMO ENGINE FOR GROWTH ACROSS 4 MAJOR INDUSTRIES COSMETICS/FRAGRANCES NUTRACEUTICALS STATUS STATUS COMPLETED STAGE 1 ADVANCED STEP IN STAGE 1 MULTI-BILLION $ CONSUMER FUND PHARMA & BIOTECH NUTRITION & SWEETENERS Anchored by Dec. 2024 Deal with Tate & Lyle STATUS STATUS COMPLETED STAGE 1 2 COMPOUNDS
Slide 23: Staged Development Approach to Ensure Success
STAGED DEVELOPMENT APPROACH TO ENSURE SUCCESS WHILST GENERATING REVENUE NEW DISCOVERY Stage Stage 1 Stage 2 Stage 3 MANUFACTURING SHORT LIST OF PLANT PREDICTOR & SELECTOR CORRECTOR & LARGE SCALE & INDUSTRIAL & COMPOUNDS FOR SAMPLER PRODUCER COMMERCIAL CUSTOMER 1 MONTH 6 -9 MONTHS 6 – 9 MONTHS 6 – 9
Slide 24: The CDMO Sales Funnel
THE CDMO SALES FUNNEL: CURRENT CUSTOMER PROGRESS BOTANICAL SYNTHESIS LAB-TO-CUSTOMER PROCESS IN FULL EFFECT INDUSTRIAL & COMMERCIAL STAGE 1 STAGE 2 STAGE 3 VIABILITY Formulation Olive Cell Complete Compound Nasdaq-listed Milestone Advancement of CDMO Client to Pharma Client Stage 2 Achieved in Q1 20
Slide 25: Current Customer Future Revenue Potential
CURRENT CUSTOMER FUTURE REVENUE POTENTIAL CAN DELIVER ESTIMATED >$50M IN ANNUAL REVENUE IN COMMERCIAL MANUFACTURING PHASES POTENTIAL EST ANNUAL CURRENT BHST OWNERSHIP REVENUE BY PROJECT AT INDICATION/USE BIOHARVEST ADVANTAGE MARKET SIZE IN COMPOUND MANUFACTURING PHASE 2+YRS OUT Product Consistency P
Slide 26: In-House Biotech Manufacturing and R&D Facilities
IN-HOUSE BIOTECH MANUFACTURING AND R&D FACILITIES World-Class Biological Production and R&D Team in Israel Best in Class ROI given low Capex Requirements • Production and Corporate facility located in Yavneh, Israel • R&D offices located in Rehovot, Israel Yavneh Facility #1 Yavne Facility #2 (in pr
Slide 27: Financial Highlights
Quarterly Revenue* FINANCIAL HIGHLIGHTS $ in Millions • Investing for Growth and Profitability: scale VINIA® sales and develop incremental new products creating a defined path to near-term adjusted EBITDA breakeven with improving profit margins • Scalable CDMO Platform with Robust Pipeline: Recently
Slide 28: BioHarvest Investment Summary
BIOHARVEST INVESTMENT SUMMARY 1 2 3 Successful D2C Health & Expansive CDMO Breakthrough Technology Wellness Products Division Opportunity Brings Life-changing Compounds to Commercial 4 commercial deals signed + robust Validated Botanical Synthesis Technology Markets pipeline 4 5 6 Proprietary New Co
Slide 29: Contact Us
CONTACT US BioHarvest Sciences (Nasdaq: BHST) 625 Howe Street Suite 1140 Vancouver, BC V6C 2T6 Canada www.bioharvest.com NASDAQ: BHST 29
BioHarvest Sciences — Investor Presentation (May 2026) on 6ix